Loading...

ADC Therapeutics SA (NYSE:ADCT)

7.89 USD +1.01 USD ( +14.68% )
Watchlist Manager
ADC Therapeutics SA
NYSE:ADCT
Watchlist

EV/EBIT
Enterprise Value to EBIT

The Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
=
Enterprise Value
/
EBIT
Current EV/EBIT
ADCT
-2
Median EV/EBIT
ADCT
N/A
Industry EV/EBIT
Biotechnology
2.5

EV/EBIT History

Statistics
Enterprise Value to EBIT

1 Year 3 Years 5 Years
Average -5 -2.8 -1.7
Median -5.1 N/A N/A
Min -7.7 N/A N/A
Max -1.6 -1.6 -1.6

History Chart
Enterprise Value to EBIT

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.9
2-Years Forward
EV/EBIT
-1.7
3-Years Forward
EV/EBIT
-2.2

EV/EBIT Across Competitors

ADCT Competitors
ADC Therapeutics SA Competitors

Country Company Market Cap EV/EBIT
CH
ADC Therapeutics SA
NYSE:ADCT
606M USD N/A
US
Abbvie Inc
NYSE:ABBV
269B USD 16.1
US
Amgen Inc
NASDAQ:AMGN
131B USD 20
AU
CSL Ltd
ASX:CSL
128B AUD 29.4
US
Gilead Sciences Inc
NASDAQ:GILD
79.2B USD 7.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
74.8B USD 22.2

Relative Valuation Report

View full relative valuation report for ADC Therapeutics SA, which takes into account all ADCT`s valuation multiples.

See Also

Similar Stocks